Exonics Biopharmaceuticals Pvt Ltd
Building India's first AI-enabled BBB-targeted regenerative platform for CNS therapeutics.
Exonics Biopharmaceuticals is a biotechnology company developing next-generation therapeutics
for multiple sclerosis (MS), leukodystrophies, neuromyelitis optica spectrum disorder (NMOSD),
and other demyelinating disorders. Founded in 2025, Exonics combines AI-assisted drug discovery,
advanced disease modelling, and nanovesicle-based drug delivery to address major unmet needs
in neurological disease.
DPU FIIE Incubated Startup – 17 Sept 2026
Founder Director – Dr. Anusha Aditya
Grants applied: NBEC (CCMB, Bangalore), Blockchain for Impact (BFI), TIE, Vande Bharatam, IndieBio (USA), SBIR (USA)